BC Innovations | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
BC Innovations | Jan 29, 2019
Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest polymer vesicles loaded with the STING agonist cGAMP could help treat melanoma. The vesicles consist of cGAMP encapsulated in a polyethylene glycol (PEG)-based polymer membrane based on pH-sensitive, cationic diethylamino-based...
BC Week In Review | Dec 21, 2018
Company News

Lilly licenses Aduro's STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
BC Extra | Dec 19, 2018
Company News

Lilly licenses Aduro’s STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
BC Extra | Nov 6, 2018
Preclinical News

Codiak’s exosomes could offer new tack to STING agonism

Exosome company Codiak BioSciences Inc. (Cambridge, Mass.) on Tuesday provided a first glimpse of preclinical data for its exoSTING program, with a therapy that is among the next generation of STING agonists that go beyond...
BC Week In Review | Oct 26, 2018
Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. Merck...
BC Extra | Oct 22, 2018
Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

New data for next generation immuno-oncology agents add to the debate of whether and how agents that show no efficacy as monotherapies in Phase I trials should be advanced to later stage combination trials. This...
BC Innovations | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
BC Innovations | May 15, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and...
Items per page:
1 - 10 of 31